New Targeted Therapies for Non-Small Cell Lung Cancer
The NCCN Guidelines® Non-Small Cell Lung Cancer are updated frequently throughout the year to include new approved agents and indications. It is difficult for clinicians to stay up-to-date on the most recent recommendations to improve outcomes for their patients with metastatic NSCLC. In addition, clinicians need to be aware of novel adverse reactions that may occur with the new targeted therapies.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Managing Cancer Pain in the U.S. Opioid Crisis
To ensure safe access to opioid pain medications for patients with cancer, all members of the healthcare team need to understand the benefits of opioids, how to navigate the federal and state programs regulating opioid use, and how to develop strategies to prevent opioid misuse.
Category
  • Pain
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Neuroendocrine Tumors
Clinicians need to stay current on the knowledge of benefits and risks, including the potential for lifetime radiation toxicity, of the multiple acceptable treatment strategies and apply high-level clinical evidence and expert advice to individualize the treatment and maximize outcomes.
Category
  • Neuroendocrine Tumors
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Immunotherapies in Non-Small Cell Lung Cancer
Immunotherapy recommendations for patients with thoracic cancers are rapidly changing, and health care providers are challenged to remain aware of the most current recommendations in the NCCN Guidelines® to improve outcomes for their patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentations from the NCCN 2019 Congress Series™: Lung Cancer
The American Cancer Society (ACS) estimates that 228,150 new cases of lung cancer will be diagnosed in the United States in 2019 with an estimated 142,670 estimated deaths, with smoking remaining an important risk factor.  The emergence of new biomarker testing, advances in radiation techniques,
Category
Format
Credits
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2020
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN.
Category
  • Myeloid Growth Factors
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
BCOP Test - Emerging Strategies for Pediatric Acute Lymphoblastic Leukemia Management
To be eligible to take the BCOP test, you must first complete all credit requirements for the educational activity. The test is available for an additional fee of $49. Each activity is this series is worth 1 hour of BCOP credit.
Category
Format
Credits
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
BCOP Test - Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
To be eligible to take the BCOP test, you must first complete all credit requirements for the educational activity. The test is available for an additional fee of $49. Each activity is this series is worth 1 hour of BCOP credit.
Category
Format
Credits

Pages